Golden Retriever Muscular Dystrophy (GRMD) is a dystrophin-deficient canine model genetically homologous to Duchenne Muscular Dystrophy (DMD) in humans. Muscular fibrosis secondary to cycles of degeneration/regeneration of dystrophic muscle tissue and muscular weakness leads to biomechanical adaptation that impairs the quality of gait. Physical therapy (PT) is one of the supportive therapies available for DMD, however, motor PT approaches have controversial recommendations and there is no consensus regarding the type and intensity of physical therapy. In this study we investigated the effect of physical therapy on gait biomechanics and muscular collagen deposition types I and III in dystrophin-deficient dogs. Two dystrophic dogs (treated dogs-TD) underwent a PT protocol of active walking exercise, 3×/week, 40 minutes/day, 12 weeks. Two dystrophic control dogs (CD) maintained their routine of activities of daily living. At t0 (pre) and t1 (post-physical therapy), collagen type I and III were assessed by immunohistochemistry and gait biomechanics were analyzed. Angular displacement of shoulder, elbow, carpal, hip, stifle and tarsal joint and vertical (Fy), mediolateral (Fz) and craniocaudal (Fx) ground reaction forces (GRF) were assessed. Wilcoxon test was used to verify the difference of biomechanical variables between t0 and t1, considering p<.05. Type I collagen of endomysium suffered the influence of PT, as well as gait speed that had decreased from t0 to t1 (p<.000). The PT protocol employed accelerates morphological alterations on dystrophic muscle and promotes a slower velocity of gait. Control dogs which maintained their routine of activities of daily living seem to have found a better balance between movement and preservation of motor function.
References
[1]
Collins CA, Morgan JE (2003) Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 84: 165–172. doi: 10.1046/j.1365-2613.2003.00354.x
[2]
Ambrosio CE, Fadel L, Gaiad TP, Martins DS, Araújo KPC, et al. (2009) Identification of three distinguishable phenotypes in golden retriever muscular dystrophy. Genet Mol Res 8 (2) 389–396. doi: 10.4238/vol8-2gmr581
[3]
Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, et al. (2012) Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 23 (1–2) 85–108 doi: 10.1007/s00335-011-9382-y.
[4]
Valentine BA, Cooper BJ, Cummings JF, de Lahunta A (1990) Canine X-linked muscular dystrophy: morphologic lesions. J Neurol Sci 97: 1–23. doi: 10.1016/0022-510x(90)90095-5
[5]
Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in b normal and affected individuals. Cell 50 (3) 509–517. doi: 10.1016/0092-8674(87)90504-6
[6]
Gaiad TP, Araujo KPC, Caromano F, Ambrosio CE (2012) Duchenne Muscular Dystrophy: Experimental models on Physical Therapy. In: Hegde M, Ankala A, editors. Muscular Dystrophy. Rijeka, Croatia: InTech. pp. 535–544. doi: 10.5772/30329
[7]
Gaiad TP, Miglino MA, Zatz M, Hamlett WC, Ambrosio CE (2009) Effect of physical therapy on joint range of motion and muscle collagen deposition in the Golden Retriever Muscular Dystrophy (GRMD) model. Rev Bras Fisioter 13 (3) 244–51. doi: 10.1590/s1413-35552009005000032
Carter GT, Abresch RT, Fowler WM Jr (2008) Adaptations to exercise training and contraction-induced muscle injury in animal models of muscular dystrophy. Am J Phys Med Rehabil 81 (Suppl 11) 151–61. doi: 10.1097/00002060-200211001-00016
[10]
Cup EH, Pieterse AJ, ten Broek-Pastoor JM, Munneke M, van Engelen BG, et al. (2007) Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil 88: 1452–64. doi: 10.1016/j.apmr.2007.07.024
[11]
Nguyen F, Cherel L, Guigand I, Goubault-Leroux I, Wyers M (2002) Muscle lesions associated with dystrophin deficiency in neonatal Golden Retriever puppies. J Comp Pathol 126: 100–108. doi: 10.1053/jcpa.2001.0526
[12]
Passerini L, Bernasconi P, Baggi F, Confalonieri P, Cozzi F, et al. (2002) Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscul Disord 12 (9) 828–835. doi: 10.1016/s0960-8966(02)00071-8
[13]
Doglio L, Pavan E, Pernigotti I, Petralia P, Frigo C, et al. (2011) Early signs of gait deviation in Duchenne muscular dystrophy. Eur J Phys Rehabil Med 47 (4) 587–594. doi: 10.1016/j.gaitpost.2008.10.044
[14]
Ganea R, Jeannet P-Y, Paraschiv-Ionescu A, Goemans N, Piot C, et al. (2012) Gait Assessment in Children With Duchenne Muscular Dystrophy During Long-Distance Walking. J Child Neurol 27 (1) 30–38 doi: 10.1177/0883073811413581.
[15]
Gaiad TP, Silva MB, Silva GCA, Caromano FA, Miglino MA, et al. (2011) Physical therapy assessment tools to evaluate disease progression and phenotype variability in Golden Retriever muscular dystrophy. Res Vet Sci 91: 188–193. doi: 10.1016/j.rvsc.2011.01.007
[16]
Kerkis I, Ambrosio CE, Kerkis A, Martins DS, Zucconi E, et al. (2008) Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: local or systemic? Journal of Translational Medicine 6: 35 doi:10.1186/1479-5876-6-35.
[17]
Thibaud JL, Monnet A, Bertoldi D, Barthelémy I, Blot S, et al. (2007) Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging. Neuromuscul Disord 17: 575–584. doi: 10.1016/j.nmd.2007.03.013
[18]
Barthélémy I, Barrey E, Thibaud JL, Uriarte A, Voit T, et al. (2009) Gait analysis using accelerometry in dystrophin-deficient dogs. Neuromuscul Disord 19 (11) 788–796. doi: 10.1016/j.nmd.2009.07.014
[19]
Marsh AP, Eggebeen JD, Kornegay JN, Markert CD, Childers MK (2010) Kinematics of gait in Golden Retriever Muscular Dystrophy. Neuromuscul Disord 20 (1) 16–20. doi: 10.1016/j.nmd.2009.10.007
[20]
Barthélémy I, Barrey E, Aguilar P, Uriarte A, Le Chevoir M, et al. (2011) Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs. BMC Musculoskeletal Disorders 12: 75 doi:10.1186/1471-2474-12-75.
[21]
Shin J-H, Greer B, Hakim CH, Zhou Z, Chung Y-C, et al. (2013) Quantitative Phenotyping of Duchenne Muscular Dystrophy Dogs by Comprehensive Gait Analysis and Overnight Activity Monitoring. PLoS ONE 8 (3) e59875 doi:10.1371/journal.pone.0059875.
[22]
Barthélémy I, Uriarte A, Drougard C, Unterfinger Y, Thibaud J-L, et al. (2012) Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne Muscular Dystrophy. PLoS ONE 7 (11) e48478 doi:10.1371/journal.pone.0048478.
[23]
Eagle M (2002) Report on the muscular dystrophy campaign workshop: Exercise in neuromuscular diseases. Neuromuscul Disord 12 (10) 975–983. doi: 10.1016/s0960-8966(02)00136-0
[24]
Ansved T (2003) Muscular dystrophies: influence of physical conditioning on the disease. Curr Opin Clin Nutr Metab Care 6 (4) 435–9. doi: 10.1097/00075197-200307000-00013
[25]
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177–89. doi: 10.1016/s1474-4422(09)70272-8
[26]
Cup EH, Pieterse AJ, ten Broek-Pastoor JM, Munneke M, van Engelen BG, et al. (2007) Exercise Therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil 88: 1452–64. doi: 10.1016/j.apmr.2007.07.024
[27]
Howell JM, Fletcher S, Kakulas BA, O'Hara M, Lochmuller H, et al. (1997) Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. Neuromuscul Disord 7 (5) 325–8. doi: 10.1016/s0960-8966(97)00057-6
[28]
McLoon LK (2008) Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy. Am J Physiol 294: 1505–1507. doi: 10.1152/ajpheart.00176.2008
[29]
Cozzi F, Cerletti M, Luvoni GC, Lombardo R, Brambilla PG, et al. (2001) Development of muscle pathology in canine X-linked muscular dystrophy. II Quantitative characterization of histopathological progression during postnatal skeletal muscle development. Acta Neuropathol 101: 469–478.
[30]
Desguerre I, Mayer M, Leturcq F, Barbet J-P, Gherardi RK, et al. (2009) Endomysial fibrosis in Duchenne Muscular Dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 68 (7) 762–773. doi: 10.1097/nen.0b013e3181aa31c2
[31]
Alexakis C, Partridge T, Bou-Gharios G (2007) Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am J Physiol 293: 661–669. doi: 10.1152/ajpcell.00061.2007
[32]
Zhou L, Lu H (2010) Targeting Fibrosis in Duchenne Muscular Dystrophy. J Neuropathol Exp Neurol 69 (8) 771–776. doi: 10.1097/nen.0b013e3181e9a34b
[33]
Huang P, Zhao XS, Fields M, Ransohoff RM, Zhou L (2009) Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J 23 (8) 2539–2548. doi: 10.1096/fj.09-129833
[34]
Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE (2008) Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am J Physiol 294: 1550–1561. doi: 10.1152/ajpheart.01253.2007
[35]
Van der Walt AM, Stewart AV, Joubert KE, Bekker P (2008) Canine hip extension range during gait. J S Afr Vet Assoc 79 (4) 175–77. doi: 10.4102/jsava.v79i4.269
[36]
Lee D, Stakebake E, Walter R, Carrier D (2004) Effects of mass distribution on the mechanics of level trotting in dogs. J Exp Biol 207: 1715–1728. doi: 10.1242/jeb.00947
[37]
Besancon MF, Conzemius MG, Evans RB, Ritter MJ (2004) Distribution of vertical forces in the pads of Greyhounds and Labrador Retrievers during walking. Am J Vet Res 65 (11) 1497–1501. doi: 10.2460/ajvr.2004.65.1497
[38]
Gillette RL, Angle TC (2008) Recent developments in canine locomotor analysis: a review. Vet J 178: 165–176. doi: 10.1016/j.tvjl.2008.01.009
[39]
Abdelhadi J, Wefstaedt P, Nolte I, Schilling N (2012) Fore-aft ground force adaptations to induced forelimb lameness in walking and trotting dogs. PLoS One 7 (12) e52202. doi: 10.1371/journal.pone.0052202
[40]
Meij BP, Suwankong N, Van den Brom WE, Vender-Van Haagen AJ, Hazewinkel HA (2006) Tibial nerve somatosensory evoked potentials in dogs with degenerative lumbosacral stenosis. Vet Surg 35: 168–175. doi: 10.1111/j.1532-950x.2006.00128.x
[41]
Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, et al. (2013) Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther 21 (4) 750–7. doi: 10.1038/mt.2012.283
[42]
Araujo KP, Bonuccelli G, Duarte CN, Gaiad TP, Moreira DF, et al. (2013) Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs. PLoS One 8;8 (4) e61367. doi: 10.1371/journal.pone.0061367
